We're at #IBDInnovate2026! Seres' Elizabeth Halvorsen, Ph.D., is presenting research on two potential biomarkers that may help predict patient outcomes and identify those most likely to benefit from live biotherapeutics. 📌Poster: Today, 4–6 PM ET 📌Oral: Oct. 20, 2:45–3 PM ET

We're excited to attend #IDWeek2026 next week in Washington, D.C.! On Thursday, October 22, our team will present a poster highlighting preclinical data supporting the development of SER-428, an investigational oral liquid live biotherapeutic designed to reduce the risk of bloodstream infections in medically vulnerable patients following sepsis and antibiotic exposure. We look forward to connecting with the infectious disease community and sharing our latest research. Read more in today's release: ir.serestherapeutics.com/new…

Seres has received the second $12.5 million payment from Nestlé Health Science in October 2026, as expected, completing the aggregate $25 million paid to buy out potential future VOWST® net sales-based milestones, related to the previously-announced transaction.

This morning we announced our Q2 2026 financial results and provided business updates. Read the release: ir.serestherapeutics.com/new…

We’re excited to share encouraging results from an IST conducted by @MSKCancerCenter evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis (irEC). We will host a webcast today at 8:30am EST. More info and webcast details: ir.serestherapeutics.com/new…

This morning we announced our Q1 2026 financial results and provided business updates. Read the release: ir.serestherapeutics.com/new…

This morning we reported our Q4 and full year 2025 financial results and provided business updates. Read more: ir.serestherapeutics.com/new…

Today we announced the appointment of Richard Kender as Executive Chair and Interim CEO and provided additional corporate updates. We will be hosting a conference call tomorrow, March 3, at 8:30 am ET. More info: ir.serestherapeutics.com/new…

We’re excited to share the publication of two manuscripts in @NatureMedicine and @JIDJournal highlighting new insights into the functional mechanism and clinical impact of VOWST™. Read More: ir.serestherapeutics.com/new…

We’re looking forward to participating in a fireside chat at the Piper Sandler Healthcare Conference on December 2 at 10:30 AM EST. Read more:ir.serestherapeutics.com/new…

This morning our team reported Q3 financial results and business updates. We will be holding a conference call at 8:30am EST – more details and dial-in information can be found in today’s press release: ir.serestherapeutics.com/new…

Mark your calendars—our team will be sharing Q3 earnings and business updates next Wednesday, November 5 at 8:30am EST. Details and conference call information can be found here: ir.serestherapeutics.com/new…

We’re excited to share that @CARB_X will provide Seres with up to $3.6M to support development and manufacturing of an oral liquid formulation of SER-155 for medically vulnerable patient populations who cannot be dosed with oral capsules. ir.serestherapeutics.com/new…

We’re looking forward to presenting at #IDWeek2025 in Atlanta next week! Dr. Tessa Andermann, Associate Professor of Medicine at UNC Chapel Hill, will share new post hoc data from our SER-155 Phase 1b trial. Read more: ir.serestherapeutics.com/new…

The Seres management team will be attending the upcoming H.C. Wainwright Global Investment Conference in New York City and will present a company overview on September 8th at 3pm EST. Read more: ir.serestherapeutics.com/new…

This morning our team reported Q2 2025 financial results and business updates. We will also be holding a conference call at 8:30am EST, and a webcast will be available approximately two hours following the event. Full release: ir.serestherapeutics.com/new…

Mark your calendars—our team will be sharing Q2 earnings and business updates this Wednesday, August 6 at 8:30am EST. Details and conference call information can be found here: ir.serestherapeutics.com/new…

We’re excited to present new SER-155 Phase 1b exploratory biomarker data at #ASCO25. If you’re attending, we welcome you to stop by our poster and learn more! Read more: ir.serestherapeutics.com/new…

This morning we shared our Q1 results and business updates. SER-155 is planning for a Phase 2 following FDA feedback, with new exploratory biomarker data supporting its potential in BSIs and broader immune/inflammatory diseases. Strategic partnership discussions for SER-155 are underway. ir.serestherapeutics.com/new…

We’re looking forward to sharing our Q1 2025 financial results and business updates this Wednesday, May 7 at 8:30am EST. Dial-in info can be found in our recent release: ir.serestherapeutics.com/new…